恩威斯塔控股
NVST
22.90
-0.60
-2.55%
恩威斯塔控股
US · NVST
#2329 按市值排名
上市于 2019
22.90
-0.60
-2.55%
实时 - 追踪5344个代码 - 心跳于514秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.5个百分点。
机构持股
- 机构持股比例
- 119.40% +0.48pp
- 机构数量
- 451
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund95.52%
Hedge Fund17.11%
Public Company2.28%
Government Pension Fund1.42%
Sovereign Wealth Fund1.37%
Private Company0.93%
Individual/Insider0.39%
Insurance Company0.35%
Family Office/Trust0.34%
主要股东 截至 2026-06-30
BlackRock
11.48% · 18.44M 股
Ariel Investments, LLC
6.11% · 9.82M 股
Dimensional Fund Advisors
5.96% · 9.57M 股
Vanguard Capital Management, LLC
5.21% · 8.37M 股
Vanguard Portfolio Management, LLC
4.66% · 7.49M 股
Eaton Vance Management
3.70% · 5.95M 股
Gates Capital Management, Inc.
3.46% · 5.55M 股
State Street Global Advisors
3.32% · 5.33M 股
AllianceBernstein
3.25% · 5.21M 股
Arrowstreet Capital, Limited Partnership
3.02% · 4.85M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 14次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Paul Keel | Chief Executive Officer | 0.10% |
| Amir Aghdaei | Chief Executive Officer | 0.08% |
| Barbara Hulit | Independent Director | 0.04% |
| Mark Nance | Senior Vice President | 0.04% |
| Eric Hammes | Chief Financial Officer | 0.03% |
| Stefan Nilsson | President of Nobel Biocare | 0.02% |
| Faez Kaabi | VP, Chief Accounting Officer & Corporate Controller | 0.02% |
| Robert Befidi | President of Diagnostics | 0.02% |
| Mischa Reis | Senior Vice President of Strategy & Corporate Development | 0.02% |
| Veronica Acurio | President of Orthodontics- Ormco | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-24 | Robert Befidi | President of Diagnostics | Sale to Issuer | -5,147 | $27.47 |
| 2026-08-24 | Eric Hammes | Chief Financial Officer | Sale to Issuer | -10,885 | $27.47 |
| 2026-08-24 | Veronica Acurio | President of Orthodontics- Ormco | Sale to Issuer | -7,710 | $27.47 |
| 2026-08-24 | Stefan Nilsson | President of Nobel Biocare | Sale to Issuer | -804 | $27.47 |
| 2026-08-19 | Mischa Reis | Senior Vice President of Strategy & Corporate Development | Automatic Disposition | -8,000 | $27.50 |
| 2026-08-17 | Paul Keel | Chief Executive Officer | Other Acquisition | +179,730 | -- |
| 2026-08-17 | Paul Keel | Chief Executive Officer | Other Derivative Acquisition | +159,900 | -- |
| 2026-08-17 | Eric Hammes | Chief Financial Officer | Other Derivative Acquisition | +47,970 | -- |
| 2026-08-05 | Coree Thomas | Vice President & Global Controller | Initial Statement of Beneficial | 0 | -- |
| 2026-05-24 | Paul Keel | Chief Executive Officer | Sale to Issuer | -12,811 | $23.43 |
| 2026-05-18 | Daniel Raskas | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Christine Tsingos | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Kieran Gallahue | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Richard Huennekens | Independent Chairperson | Other Acquisition | +12,585 | -- |
| 2026-05-18 | Vivek Jain | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Wendy Carruthers | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | J. Pierce | Director | Other Acquisition | +9,330 | -- |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Sale to Issuer | -11,840 | $29.59 |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Other Acquisition | +48,670 | -- |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Other Derivative Acquisition | +115,320 | $29.59 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
恩威斯塔控股 讨论区 0 条评论